<DOC>
	<DOCNO>NCT00303459</DOCNO>
	<brief_summary>COMPASS-2 Phase 4 , prospective , randomize , double-blind , placebo-controlled , event-driven study evaluate effect bosentan time first confirm morbidity/mortality event patient symptomatic PAH already receive sildenafil therapy . Patients must receive dos sildenafil equal great 20 mg t.i.d . least 12 week prior randomize . The study continue predefined target number morbidity/mortality event reach .</brief_summary>
	<brief_title>Effects Combination Bosentan Sildenafil Versus Sildenafil Monotherapy Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Signed informed consent prior initiation studymandated procedure 2 . Males females &gt; =12 year age ( except country age limit contrary specific regulatory requirement ) . Women childbearing potential must negative pretreatment pregnancy test must use reliable method contraception study treatment least 3 month study treatment termination . Â·Reliable method contraception : O Barrier type device ( e.g. , female condom , diaphragm , contraceptive sponge ) combination spermicide . O Intrauterine device . O Oral , transdermal , injectable implantable contraceptive combination barrier method . Hormonebased contraceptive alone , regardless route administration , consider reliable method contraception . Abstention , rhythm method , contraception partner alone acceptable method contraception . Women childbearing potential define postmenopausal ( i.e. , amenorrhea least 1 year ) , document surgically naturally sterile . 3 . Patients symptomatic PAH 4 . Patients follow type PAH belonging WHO Group I : Idiopathic ( IPAH ) Familial ( FPAH ) Associated ( APAH ) : i. Collagen vascular disease normal leave ventricular function ( ejection fraction ( EF ) &gt; 50 % ) ii . Congenital systemictopulmonary shunt least 2 year post surgical repair iii . Drugs toxins 5 . PAH diagnose right heart catheter showing : Mean pulmonary arterial pressure ( mPAP ) &gt; = 25 mm Hg AND Pulmonary capillary wedge pressure ( PCWP ) = &lt; 15 mm Hg leave ventricular end diastolic pressure ( LVEDP ) = &lt; 15 mmHg If PCWP LVEDP available LVEDP value retain inclusion . 6 . Treatment stable dose sildenafil equal great 20 mg t.i.d . least 12 week prior randomization ( sildenafil dosage adjustment occur period ) 7 ) 150 = &lt; 6minute walk test ( 6MWT ) = &lt; 480 , document 2 test second 6MWT within 15 % first 6MWT distance third test require Exclusion Criteria : 1 . PAH belong WHO group IIV 2 . PAH associate portal hypertension HIV infection 3 . PAH associate thyroid disorder , glycogen storage disease , Gaucher disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder splenectomy 4 . PAH associate significant venous capillary involvement ( PCWP &gt; 15 mmHg ) : pulmonary venoocclusive disease pulmonary capillary hemangiomatosis 5 . Persistent pulmonary hypertension newborn 6 . Significant valvular disease valvular lesion exclude echocardiogram within 2 year prior randomization ( i.e . patient tricuspid pulmonary insufficiency secondary PAH include ) 7 . Restrictive lung disease : total lung capacity ( TLC ) &lt; 60 % normal predict value ( see Appendix 3 ) 8 . Obstructive lung disease : forced expiratory volume/forced vital capacity ( FEV1/FVC ) &lt; 0.5 9 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C 10 . Known HIV infection 11 . Acute chronic impairment ( dyspnea ) , limit ability comply study requirement may interfere safety evaluation study , chronic infection , chronic renal failure etc . 12 . Psychotic , addictive disorder limit ability provide inform consent comply study requirement 13 . Pregnancy breastfeed 14 . Condition prevents compliance protocol adherence therapy 15 . Systolic blood pressure &lt; 85 mmHg 16 . Body weight &lt; 40 kg 17 . Hemoglobin &lt; 75 % low limit normal range 18 . Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal range 19 . Known hypersensitivity history drugrelated adverse event bosentan ( e.g . increase liver function test result ) , excipients formulation 20 . Receipt investigational product sildenafil within 3 month start study treatment 21 . Treatment endothelin receptor antagonist ( ERAs ) , prostanoids phosphodiesterase ( PDE ) 5 inhibitor sildenafil within 3 month prior randomization 22 . Concomitant systemic treatment within 1 week prior randomization calcineurin inhibitor ( e.g. , cyclosporine A tacrolimus ) , sirolimus everolimus glibenclamide ( glyburide ) cytochrome P2C9 ( CYP2C9 ) cytochrome P3A4 ( CYP3A4 ) ( e.g. , fluconazole , amiodarone , voriconazole ) combination drug inhibit CYP2C9 CYP3A4 23 . Treatment nitrate alphablockers time randomization 24 . In opinion investigator patient need treatment prostanoid Visit 4 25 . Significant leave ventricular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>sildenafil</keyword>
	<keyword>Combination Drug Therapy</keyword>
	<keyword>bosentan</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Multicenter Study</keyword>
	<keyword>Antihypertensive Agents</keyword>
	<keyword>Tracleer</keyword>
	<keyword>endothelin receptor antagonist</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Phosphodiesterase type 5 inhibitor ( PDE5i )</keyword>
	<keyword>Outcome Assessment</keyword>
</DOC>